The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Major study data to look out for from ASH 2020
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci, Barts Cancer Institute, London, UK shares key study data to lookout for at ASH 2020. Early trials for many novel agents in both acute myeloid leukemia (AML) and multiple myeloma will be presented. Of particular interest to Prof. Gribben is the upcoming results of trials in follicular lymphoma, such as bispecific antibodies and CD19 CAR-T cells. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
